Gonelli C, King H, Ko S, Fennessey C, Iwamoto N, Mason R
Nature. 2025; 639(8053):205-213.
PMID: 39910294
PMC: 11882457.
DOI: 10.1038/s41586-024-08500-y.
King H, Brammer D, Lewitus E, Fennessey C, Manalang K, Shrader H
Proc Natl Acad Sci U S A. 2025; 122(5):e2404767122.
PMID: 39883843
PMC: 11804569.
DOI: 10.1073/pnas.2404767122.
Cohen P, Lambson B, Mkhize N, Moodley C, Yssel A, Moyo-Gwete T
J Virol. 2025; 99(2):e0173024.
PMID: 39817771
PMC: 11852940.
DOI: 10.1128/jvi.01730-24.
Smith J, Arunachalam P, Legere T, Cavacini L, Hunter E, Pulendran B
Vaccines (Basel). 2025; 12(12.
PMID: 39772048
PMC: 11680376.
DOI: 10.3390/vaccines12121386.
DeLaitsch A, Keeffe J, Gristick H, Lee J, Ding W, Liu W
NPJ Vaccines. 2024; 9(1):240.
PMID: 39638818
PMC: 11621127.
DOI: 10.1038/s41541-024-01038-0.
Berberine: A dual anti-HIV and anti- cervical cancer compound.
Naushad W, Okeoma B, Islam H, Wang Z, Yang N, Li X
Res Sq. 2024; .
PMID: 39606456
PMC: 11601857.
DOI: 10.21203/rs.3.rs-5479739/v1.
Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity.
Upadhyay C, Rao P, Behzadi M, Feyznezhad R, Lambert G, Kumar R
Front Immunol. 2024; 15():1476924.
PMID: 39380992
PMC: 11458420.
DOI: 10.3389/fimmu.2024.1476924.
Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines.
Schwarzmuller M, Lozano C, Schanz M, Abela I, Grosse-Holz S, Epp S
Cell Rep Med. 2024; 5(9):101702.
PMID: 39216479
PMC: 11524982.
DOI: 10.1016/j.xcrm.2024.101702.
Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains.
Wang S, Chan K, Wei D, Ma X, Liu S, Hu G
Nat Commun. 2024; 15(1):4301.
PMID: 38773089
PMC: 11109196.
DOI: 10.1038/s41467-024-48514-8.
Genetically Engineered Microorganisms and Their Impact on Human Health.
Mahdizade Ari M, Dadgar L, Elahi Z, Ghanavati R, Taheri B
Int J Clin Pract. 2024; 2024:6638269.
PMID: 38495751
PMC: 10944348.
DOI: 10.1155/2024/6638269.
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.
Lim S, Lee J, Osuna C, Vikhe P, Schalk D, Chen E
Science. 2024; 383(6687):1104-1111.
PMID: 38422185
PMC: 11022498.
DOI: 10.1126/science.adf7966.
IFITM1 and IFITM3 Proteins Inhibit the Infectivity of Progeny HIV-1 without Disrupting Envelope Glycoprotein Clusters.
Verma S, Chen Y, Marin M, Gillespie S, Melikyan G
Viruses. 2023; 15(12).
PMID: 38140631
PMC: 10748374.
DOI: 10.3390/v15122390.
Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States.
Wieczorek L, Sanders-Buell E, Zemil M, Lewitus E, Kavusak E, Heller J
PLoS Pathog. 2023; 19(12):e1011780.
PMID: 38055771
PMC: 10727358.
DOI: 10.1371/journal.ppat.1011780.
Conjugation of HIV-1 envelope to hepatitis B surface antigen alters vaccine responses in rhesus macaques.
Nettere D, Unnithan S, Rodgers N, Nohara J, Cray P, Berry M
NPJ Vaccines. 2023; 8(1):183.
PMID: 38001122
PMC: 10673864.
DOI: 10.1038/s41541-023-00775-y.
Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
Rao P, Lambert G, Upadhyay C
J Virol. 2023; 97(9):e0071023.
PMID: 37681958
PMC: 10537810.
DOI: 10.1128/jvi.00710-23.
Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIV acquisition in macaques.
Rahman M, Becerra-Flores M, Patskovsky Y, Silva de Castro I, Bissa M, Basu S
Front Immunol. 2023; 14:1139402.
PMID: 37153584
PMC: 10160393.
DOI: 10.3389/fimmu.2023.1139402.
Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use.
Grandits M, Grunwald-Gruber C, Gastine S, Standing J, Reljic R, Teh A
Front Plant Sci. 2023; 14:1126470.
PMID: 36923134
PMC: 10009187.
DOI: 10.3389/fpls.2023.1126470.
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
Cohen K, Fiore-Gartland A, Walsh S, Yusim K, Frahm N, Elizaga M
J Clin Invest. 2023; 133(4).
PMID: 36787249
PMC: 9927951.
DOI: 10.1172/JCI163338.
CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals.
Gristick H, Hartweger H, Loewe M, van Schooten J, Ramos V, Oliveira T
Sci Immunol. 2023; 8(80):eade6364.
PMID: 36763635
PMC: 10202037.
DOI: 10.1126/sciimmunol.ade6364.
Tenofovir-tethered gold nanoparticles as a novel multifunctional long-acting anti-HIV therapy to overcome deficient drug delivery-: an in vivo proof of concept.
Fotooh Abadi L, Kumar P, Paknikar K, Gajbhiye V, Kulkarni S
J Nanobiotechnology. 2023; 21(1):19.
PMID: 36658575
PMC: 9850711.
DOI: 10.1186/s12951-022-01750-w.